AZN ASTRAZENECA PLC IFRS
Pharmaceutical Preparations · NYSE · SEC CIK 901832 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY8.6%
TTM net income YoY45.3%
TTM EPS YoY45.3%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR46.0%
Margins
Gross margin81.9%
Operating margin23.4%
Net margin17.4%
FCF margin20.0%
EBITDA margin—
Returns
ROE22.9%
ROA9.4%
ROIC (approx.)16.8%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets57.3%
Debt / equity0.57x
Current ratio0.94x
Interest coverage8.11x
Cash quality & payout
Operating cash flow / net income1.43x
Accruals ratio-4.0%
Payout ratio48.6%
Capex / revenue4.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Cost of revenue | $10.63B | $10.21B | $8.27B | $12.39B | $12.44B |
| Gross profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B |
| R&D expense | $14.23B | $13.58B | $10.94B | $9.76B | $9.74B |
| SG&A expense | $19.93B | $19.98B | $19.22B | $18.42B | $15.23B |
| Operating income | $13.74B | $10.00B | $8.19B | $3.76B | $1.06B |
| Interest expense | $1.69B | $1.74B | $1.63B | $1.35B | $1.30B |
| Pretax income | $12.40B | $8.69B | $6.90B | $2.50B | -$265.00M |
| Income tax | $2.17B | $1.65B | $938.00M | -$792.00M | -$380.00M |
| Net income | $10.22B | $7.04B | $5.96B | $3.29B | $112.00M |
| EPS (basic) | 6.60 | 4.54 | 3.84 | 2.12 | 0.08 |
| EPS (diluted) | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 |
| Dividends declared per share | 3.13 | 2.97 | 2.90 | 2.90 | 2.80 |
| Weighted avg. shares (diluted) | 1.56B | 1.56B | 1.56B | 1.56B | 1.43B |
| Balance sheet | |||||
| Cash & equivalents | $5.71B | $5.49B | $5.84B | $6.17B | $6.33B |
| Short-term investments | $30.00M | $166.00M | $122.00M | $239.00M | $69.00M |
| Receivables | $15.18B | $12.97B | $12.13B | $10.52B | $9.64B |
| Inventory | $6.56B | $5.29B | $5.42B | $4.70B | $8.98B |
| Current assets | $28.72B | $25.83B | $25.05B | $22.59B | $26.24B |
| PP&E, netmay include right-of-use assets (IFRS) | $12.96B | $10.25B | $9.40B | $8.51B | $9.18B |
| Goodwill | $21.24B | $21.02B | $20.05B | $19.82B | $20.00B |
| Intangibles | $37.85B | $37.18B | $38.09B | $39.31B | $42.49B |
| Total assets | $114.07B | $104.03B | $101.12B | $96.48B | $105.36B |
| Current liabilities | $30.62B | $27.87B | $30.54B | $26.29B | $22.59B |
| Short-term debt | $3.10B | $2.34B | $5.13B | $5.31B | $1.66B |
| Long-term debt | $24.71B | $26.51B | $22.36B | $22.96B | $28.13B |
| Total debt | $27.82B | $28.84B | $27.49B | $28.28B | $29.79B |
| Total liabilities | $65.36B | $63.16B | $61.95B | $59.42B | $66.08B |
| Shareholders' equity | $48.67B | $40.79B | $39.14B | $37.04B | $39.27B |
| Net debt | $22.11B | $23.36B | $21.65B | $22.11B | $23.46B |
| Cash flow statement | |||||
| Operating cash flow | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B |
| Capital expenditure | $2.81B | $1.92B | $1.36B | $1.09B | $1.09B |
| Free cash flow | $11.77B | $9.94B | $8.98B | $8.72B | $4.87B |
| Investing cash flow | -$6.81B | -$7.98B | -$4.06B | -$2.96B | -$11.06B |
| Financing cash flow | -$7.54B | -$4.00B | -$6.57B | -$6.82B | $3.65B |
| Stock-based compensation | $719.00M | $660.00M | $579.00M | $619.00M | $615.00M |
| Dividends paid | $4.97B | $4.63B | $4.48B | $4.36B | $3.86B |
| Share buybacks | $521.00M | $81.00M | — | — | $149.00M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.